New company focuses on developing a disease-modifying treatment for neuropathic pain.

Press release, Friday, 2 December 2016

Hoba Therapeutics, a biotechnology company focusing on developing disease-modifying treatments for neuropathic pain, has been formed based on a DKK 14 million (US$ 2 million) seed investment. Novo Seeds, part of Novo A/S, led the financing together with Danish investor BOREAN Innovation.